Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M22.9Revenue $M14.7Net Margin (%)-216.4Altman Z-Score-9.3
Enterprise Value $M-33.5EPS $-0.5Operating Margin %-223.3Piotroski F-Score2
P/E(ttm)--Beneish M-Score-2.1Pre-tax Margin (%)-216.4Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio2.6Cash flow > EarningsN
Price/Sales1.35-y EBITDA Growth Rate %-16.2Current Ratio2.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M71.5ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with THLD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
THLDFirst Eagle Investment 2015-09-30 Reduce-0.01%$3.62 - $5.11
($4.31)
$ 0.29-93%Reduce -60.65%500,000
THLDFirst Eagle Investment 2015-06-30 Reduce$3.49 - $4.51
($4.01)
$ 0.29-93%Reduce -9.60%1,270,768
THLDFirst Eagle Investment 2015-03-31 Add$3.33 - $4.61
($3.99)
$ 0.29-93%Add 2.06%1,405,768
THLDFirst Eagle Investment 2014-12-31 Add$2.7 - $3.56
($3.02)
$ 0.29-90%Add 26.17%1,377,448
THLDFirst Eagle Investment 2014-09-30 Add$3.75 - $5.03
($4.2)
$ 0.29-93%Add 36.46%1,091,700
THLDFirst Eagle Investment 2014-03-31 Add0.01%$4.34 - $5.72
($4.92)
$ 0.29-94%Add 250.00%700,000
THLDFirst Eagle Investment 2012-12-31 Buy $3.98 - $6.55
($4.67)
$ 0.29-94%New holding200,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

THLD is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


THLD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
JAEGER WILFRED EDirector 2015-02-18Buy25,000$3.75-92.27view
Davar NipunVice President 2014-10-13Buy3,000$2.99-90.3view
YOUNGER WILLIAM H JR10% Owner 2014-10-01Sell242,396$3.77-92.31view
WHITE JAMES N10% Owner 2014-10-01Sell239,538$3.77-92.31view
SWEET DAVID E10% Owner 2014-10-01Sell229,154$3.77-92.31view
Speiser Michael L10% Owner 2014-10-01Sell227,228$3.77-92.31view
SHEEHAN ANDREW T10% Owner 2014-10-01Sell230,352$3.77-92.31view
Pullara Samuel J III10% Owner 2014-10-01Sell226,657$3.77-92.31view
GAITHER JAMES C10% Owner 2014-10-01Sell231,287$3.77-92.31view
Dyckerhoff Stefan A10% Owner 2014-10-01Sell226,657$3.77-92.31view

Press Releases about THLD :

Quarterly/Annual Reports about THLD:

    News about THLD:

    Articles On GuruFocus.com
    Tuesday Pre-Market Insights: THLD, PLL, AOL, CALL May 12 2015 
    Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 47,619 Shares Mar 15 2011 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
    Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 52,356 Shares Oct 06 2009 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 
    Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 20,000 Shares Jun 05 2009 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2009 

    More From Other Websites
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Jan 22 2016
    Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany Agree to Key Terms for the Licensing... Jan 11 2016
    Threshold Pharmaceuticals and Merck KGaA, Darmstadt, Germany Agree to Key Terms for the Licensing... Jan 11 2016
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jan 11 2016
    Threshold Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 22 2015
    After cancer drug trials crash, Peninsula biotech sheds one-third of jobs Dec 18 2015
    Threshold Pharmaceuticals Announces Workforce Reduction Dec 18 2015
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Dec 18 2015
    Threshold Pharmaceuticals Announces Workforce Reduction Dec 18 2015
    The Only Bit of "Good News" From 2015 Dec 14 2015
    5 Key BioPharma Movers That Cannot Be Ignored Dec 12 2015
    5 Companies That Absolutely Destroyed Shareholders This Past Week Dec 12 2015
    THRESHOLD PHARMACEUTICALS INC Financials Dec 08 2015
    INVESTOR UPDATE: NASDAQ/NYSE Volatility Alert for December 8, 2015 Dec 08 2015
    Peninsula biotech sinks on two cancer failures Dec 07 2015
    Why Are Investors Selling These Stocks Today? Dec 07 2015
    Why Threshold Pharma Is Imploding Dec 07 2015
    Threshold Pharmaceuticals’ stock plunges after drug trial disappoints Dec 07 2015
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 07 2015
    Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet... Dec 07 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK